Promising predictors of diabetic peripheral neuropathy in children and adolescents with type 1 diabetes mellitus.
Humans
Diabetes Mellitus, Type 1
/ complications
Diabetic Neuropathies
/ diagnosis
Male
Female
Adolescent
Child
Case-Control Studies
Biomarkers
/ blood
Neural Conduction
Phosphopyruvate Hydratase
/ blood
Predictive Value of Tests
HSP27 Heat-Shock Proteins
/ blood
Neurologic Examination
Prevalence
Heat-Shock Proteins
Molecular Chaperones
Diabetic peripheral neuropathy
Heat shock protein 27
Lipid profile
Michigan neuropathy screening instrument
Neuron specific enolase
Type 1 diabetes mellitus
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
14
06
2024
accepted:
22
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
Diabetic peripheral neuropathy (DPN) in children and adolescents with type 1 diabetes mellitus (T1DM) is a growing issue, with controversial data in the terms of prevalence and evaluation timelines. Currently, there are no clear standards for its early detection. Therefore, our aim was to assess the contribution of the Michigan neuropathy screening instrument (MNSI), lipid profile, serum neuron specific enolase (NSE), and serum heat shock protein 27 (HSP 27) to the prediction of DPN in children and adolescents with T1DM. In this case-control study, fifty children diagnosed with T1DM for at least five years were enrolled and evaluated through complete neurological examination, MNSI, and nerve conduction study (NCS). Additionally, HbA1c, lipid profile, serum NSE, and serum HSP 27 levels were measured for patients and controls. The prevalence of DPN in our study was 24% by NCS, and electrophysiological changes showed a statistically significant lower conduction velocity for the posterior tibial and sural nerves, as well as a prolonged latency period for the common peroneal and sural nerves in neuropathic patients. In these patients, older age, earlier age of diabetes onset, longer disease duration, higher total cholesterol, triglycerides, low density lipoprotein cholesterol, HbA1c, serum NSE, and HSP27 levels were observed. The MNSI examination score ≥ 1.5 cutoff point had an area under the curve (AUC) of 0.955, with 75% sensitivity and 94.74% specificity, according to receiver operating characteristic curve analysis. However, the questionnaire's cutoff point of ≥ 5 had an AUC of 0.720, 75% sensitivity, and 63% specificity, with improved overall instrument performance when combining both scores. Regarding blood biomarkers, serum NSE had greater sensitivity and specificity in discriminating neuropathic patients than HSP27 (92% and 74% versus 75% and 71%, respectively). Regression analysis revealed a substantial dependency for MNSI and serum NSE in predicting DPN in patients. Despite limited research in pediatrics, MNSI and serum NSE are promising predictive tools for DPN in children and adolescents with T1DM, even when they are asymptomatic. Poor glycemic control and lipid profile changes may play a critical role in the development of DPN in these patients, despite conflicting results in various studies.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetic peripheral neuropathy (DPN) in children and adolescents with type 1 diabetes mellitus (T1DM) is a growing issue, with controversial data in the terms of prevalence and evaluation timelines. Currently, there are no clear standards for its early detection. Therefore, our aim was to assess the contribution of the Michigan neuropathy screening instrument (MNSI), lipid profile, serum neuron specific enolase (NSE), and serum heat shock protein 27 (HSP 27) to the prediction of DPN in children and adolescents with T1DM.
METHODS
METHODS
In this case-control study, fifty children diagnosed with T1DM for at least five years were enrolled and evaluated through complete neurological examination, MNSI, and nerve conduction study (NCS). Additionally, HbA1c, lipid profile, serum NSE, and serum HSP 27 levels were measured for patients and controls.
RESULTS
RESULTS
The prevalence of DPN in our study was 24% by NCS, and electrophysiological changes showed a statistically significant lower conduction velocity for the posterior tibial and sural nerves, as well as a prolonged latency period for the common peroneal and sural nerves in neuropathic patients. In these patients, older age, earlier age of diabetes onset, longer disease duration, higher total cholesterol, triglycerides, low density lipoprotein cholesterol, HbA1c, serum NSE, and HSP27 levels were observed. The MNSI examination score ≥ 1.5 cutoff point had an area under the curve (AUC) of 0.955, with 75% sensitivity and 94.74% specificity, according to receiver operating characteristic curve analysis. However, the questionnaire's cutoff point of ≥ 5 had an AUC of 0.720, 75% sensitivity, and 63% specificity, with improved overall instrument performance when combining both scores. Regarding blood biomarkers, serum NSE had greater sensitivity and specificity in discriminating neuropathic patients than HSP27 (92% and 74% versus 75% and 71%, respectively). Regression analysis revealed a substantial dependency for MNSI and serum NSE in predicting DPN in patients.
CONCLUSIONS
CONCLUSIONS
Despite limited research in pediatrics, MNSI and serum NSE are promising predictive tools for DPN in children and adolescents with T1DM, even when they are asymptomatic. Poor glycemic control and lipid profile changes may play a critical role in the development of DPN in these patients, despite conflicting results in various studies.
Identifiants
pubmed: 39402605
doi: 10.1186/s13052-024-01774-y
pii: 10.1186/s13052-024-01774-y
doi:
Substances chimiques
Biomarkers
0
Phosphopyruvate Hydratase
EC 4.2.1.11
HSP27 Heat-Shock Proteins
0
HSPB1 protein, human
0
Heat-Shock Proteins
0
Molecular Chaperones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
215Informations de copyright
© 2024. The Author(s).
Références
American Diabetes Association. 13. Children and adolescents: standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S163–82. https://doi.org/10.2337/dc20-S013 .
doi: 10.2337/dc20-S013
Dabelea D. Diabetes in Youth-looking backwards to inform the future: Kelly West Award lecture 2017. Diabetes Care. 2018;41(2):233–40. https://doi.org/10.2337/dci17-0031 .
doi: 10.2337/dci17-0031
pmcid: 5780050
pubmed: 29358467
Akinci G, Savelieff MG, Gallagher G, Callaghan BC, Feldman EL. Diabetic neuropathy in children and youth: New and emerging risk factors. Pediatr Diabetes. 2021;22(2):132–47. https://doi.org/10.1111/pedi.13153 .
doi: 10.1111/pedi.13153
pubmed: 33205601
Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–54. https://doi.org/10.2337/dc16-2042 .
doi: 10.2337/dc16-2042
pubmed: 27999003
Jaiswal M, Lauer A, Martin CL, et al. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for diabetes in Youth follow-up cohort: a pilot study. Diabetes Care. 2013;36(12):3903–8. https://doi.org/10.2337/dc13-1213 .
doi: 10.2337/dc13-1213
pmcid: 3836139
pubmed: 24144652
Franceschi R, Mozzillo E, Di Candia F, et al. A systematic review of the prevalence, risk factors and screening tools for autonomic and diabetic peripheral neuropathy in children, adolescents and young adults with type 1 diabetes. Acta Diabetol. 2022;59(3):293–308. https://doi.org/10.1007/s00592-022-01850-x .
doi: 10.1007/s00592-022-01850-x
pubmed: 35089443
Kallinikou D, Soldatou A, Tsentidis C, et al. Diabetic neuropathy in children and adolescents with type 1 diabetes mellitus: diagnosis, pathogenesis, and associated genetic markers. Diabetes Metab Res Rev. 2019;35(7):e3178. https://doi.org/10.1002/dmrr.3178 .
doi: 10.1002/dmrr.3178
pubmed: 31083769
Yu Y. Gold Standard for diagnosis of DPN. Front Endocrinol. 2021;12:719356. https://doi.org/10.3389/fendo.2021.719356 .
doi: 10.3389/fendo.2021.719356
Viswanathan V, Ahmed Khan B, Nachimuthu S, Kumpatla S. Precision of Michigan Neuropathy Screening Instrument (MNSI) Tool for the diagnosis of Diabetic Peripheral Neuropathy among people with type 2 Diabetes-A study from South India. Int J Low Extrem Wounds Published Online March. 2023;15. https://doi.org/10.1177/15347346231163209 .
Bulut T, Demirel F, Metin A. The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2017;30(2):181–7. https://doi.org/10.1515/jpem-2016-0111 .
doi: 10.1515/jpem-2016-0111
pubmed: 27997351
Homma TK, Endo CM, Saruhashi T, et al. Dyslipidemia in young patients with type 1 diabetes mellitus. Arch Endocrinol Metab. 2015;59(3):215–9. https://doi.org/10.1590/2359-3997000000040 .
doi: 10.1590/2359-3997000000040
pubmed: 26154088
Callaghan BC, Gallagher G, Fridman V, Feldman EL. Diabetic neuropathy: what does the future hold? Diabetologia. 2020;63(5):891–7. https://doi.org/10.1007/s00125-020-05085-9 .
doi: 10.1007/s00125-020-05085-9
pmcid: 7150623
pubmed: 31974731
Jang ER, Lee CS. 7-ketocholesterol induces apoptosis in differentiated PC12 cells via reactive oxygen species-dependent activation of NF-κB and akt pathways. Neurochem Int. 2011;58(1):52–9. https://doi.org/10.1016/j.neuint.2010.10.012 .
doi: 10.1016/j.neuint.2010.10.012
pubmed: 21035514
Fujita Y, Murakami T, Nakamura A. Recent advances in biomarkers and Regenerative Medicine for Diabetic Neuropathy. Int J Mol Sci. 2021;22(5):2301. https://doi.org/10.3390/ijms22052301 . Published 2021 Feb 25.
doi: 10.3390/ijms22052301
pmcid: 7956542
pubmed: 33669048
Li J, Zhang H, Xie M, Yan L, Chen J, Wang H. NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy. Diabetes Care. 2013;36(11):3405–10. https://doi.org/10.2337/dc13-0590 .
doi: 10.2337/dc13-0590
pmcid: 3816869
pubmed: 23846809
Gruden G, Bruno G, Chaturvedi N, et al. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: a novel circulating marker for diabetic neuropathy. Diabetes. 2008;57(7):1966–70. https://doi.org/10.2337/db08-0009 .
doi: 10.2337/db08-0009
pmcid: 2453614
pubmed: 18390793
Ma CH, Omura T, Cobos EJ, et al. Accelerating axonal growth promotes motor recovery after peripheral nerve injury in mice. J Clin Invest. 2011;121(11):4332–47. https://doi.org/10.1172/JCI58675 .
doi: 10.1172/JCI58675
pmcid: 3223863
pubmed: 21965333
Echaniz-Laguna A, Geuens T, Petiot P, et al. Axonal neuropathies due to mutations in small heat shock proteins: clinical, genetic, and functional insights into novel mutations. Hum Mutat. 2017;38(5):556–68. https://doi.org/10.1002/humu.23189 .
doi: 10.1002/humu.23189
pubmed: 28144995
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281–9. https://doi.org/10.2337/diacare.17.11.1281 .
doi: 10.2337/diacare.17.11.1281
pubmed: 7821168
Herman WH, Pop-Busui R, Braffett BH et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications [published correction appears in Diabet Med. 2022;39(4):e14765]. Diabet Med. 2012;29(7):937–944. https://doi.org/10.1111/j.1464-5491.2012.03644.x
Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10(10):931–41. https://doi.org/10.1016/S1474-4422(11)70178-8 .
doi: 10.1016/S1474-4422(11)70178-8
pubmed: 21939902
Preston DC, Shapiro BE. Electromyography and neuromuscular disorders e-book: clinical electrophysiologic correlations. 3rd ed. Elsevier Health Sciences; 2012.
Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in screening, early diagnosis and Accurate Staging of Diabetic Neuropathy. Front Endocrinol (Lausanne). 2021;12:671257. https://doi.org/10.3389/fendo.2021.671257 . Published 2021 May 26.
doi: 10.3389/fendo.2021.671257
pubmed: 34122344
de Souza RJ, de Souza A, Nagvekar MD. Nerve conduction studies in diabetics presymptomatic and symptomatic for diabetic polyneuropathy. J Diabetes Complications. 2015;29(6):811–7. https://doi.org/10.1016/j.jdiacomp.2015.05.009 .
doi: 10.1016/j.jdiacomp.2015.05.009
pubmed: 26049172
ElSayed NA, Aleppo G, Aroda VR, et al. Introduction and methodology: standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S1–4. https://doi.org/10.2337/dc23-Sint .
doi: 10.2337/dc23-Sint
pubmed: 36507647
Nkonge KM, Nkonge DK, Nkonge TN. Screening for diabetic peripheral neuropathy in resource-limited settings. Diabetol Metab Syndr. 2023;15(1):55. https://doi.org/10.1186/s13098-023-01032-x . Published 2023 Mar 22.
doi: 10.1186/s13098-023-01032-x
pmcid: 10031885
pubmed: 36945043
Kaymaz S, Alkan H, Karasu U, Çobankara V. Turkish version of the Michigan Neuropathy Screening Instrument in the assessment of diabetic peripheral neuropathy: a validity and reliability study. Diabetol Int. 2020;11(3):283–92. https://doi.org/10.1007/s13340-020-00427-9 . Published 2020 Feb 21.
doi: 10.1007/s13340-020-00427-9
pmcid: 7387400
pubmed: 32802710
Dagang DJ, Diestro JD, Hamoy-Jimenez G, Isip-Tan IT, Reyes JPB. Validation of the Filipino-translated version of the Michigan neuropathy screening instrument among Filipino patients with diabetes Mellitus seen at the Philippine general hospital. J ASEAN Federation Endocr Soc. 2016;31(2):115. https://doi.org/10.15605/jafes.031.02.06 .
doi: 10.15605/jafes.031.02.06
Tinti D, Canavese C, Nobili C, et al. Neurological dysfunction screening in a cohort of adolescents with type 1 diabetes: a six-year follow-up. Front Med (Lausanne). 2024;11:1331145. https://doi.org/10.3389/fmed.2024.1331145 . Published 2024 May 9.
doi: 10.3389/fmed.2024.1331145
pubmed: 38784238
Mostofizadeh N, Hashemipour M, Roostazadeh M, Hashemi-Dehkordi E, Shahsanai A, Reisi M. The impact of poor glycemic control on lipid profile variables in children with type 1 diabetes mellitus. J Educ Health Promot. 2019;8:6. https://doi.org/10.4103/jehp.jehp_194_17 . Published 2019 Jan 29.
doi: 10.4103/jehp.jehp_194_17
pmcid: 6378828
pubmed: 30815477
Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573–83. https://doi.org/10.1038/nrneurol.2011.137 . Published 2011 Sep 13.
doi: 10.1038/nrneurol.2011.137
pubmed: 21912405
Cai Z, Yang Y, Zhang J. A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy. Sci Rep. 2021;11(1):499. Published 2021 Jan 12. https://doi.org/10.1038/s41598-020-79276-0
Fatani SH, Babakr AT, NourEldin EM, Almarzouki AA. Lipid peroxidation is associated with poor control of type-2 diabetes mellitus. Diabetes Metab Syndr. 2016;10(2 Suppl 1):S64–7. https://doi.org/10.1016/j.dsx.2016.01.028 .
doi: 10.1016/j.dsx.2016.01.028
pubmed: 26806326
Mishra N, Singh N. Blood viscosity, lipid profile, and lipid peroxidation in type-1 diabetic patients with good and poor glycemic control. N Am J Med Sci. 2013;5(9):562–6. https://doi.org/10.4103/1947-2714.118925 .
doi: 10.4103/1947-2714.118925
pmcid: 3818830
pubmed: 24251275
Salsa-Castelo M, Neves C, Neves JS, Carvalho D. Association of glycemic variability and time in range with lipid profile in type 1 diabetes. Endocrine. 2024;83(1):69–76. https://doi.org/10.1007/s12020-023-03464-x .
doi: 10.1007/s12020-023-03464-x
pubmed: 38051418
Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–50. https://doi.org/10.1056/NEJMoa032782 .
doi: 10.1056/NEJMoa032782
pubmed: 15673800
Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and risk factors for Diabetic Peripheral Neuropathy in Youth with Type 1 and type 2 diabetes: SEARCH for diabetes in Youth Study. Diabetes Care. 2017;40(9):1226–32. https://doi.org/10.2337/dc17-0179 .
doi: 10.2337/dc17-0179
pmcid: 5566278
pubmed: 28674076
Graves LE, Donaghue KC. Management of diabetes complications in youth. Ther Adv Endocrinol Metab. 2019;10:2042018819863226. https://doi.org/10.1177/2042018819863226 . Published 2019 Jul 25.
doi: 10.1177/2042018819863226
pmcid: 6659178
pubmed: 31384418
Ziegler D, Behler M, Schroers-Teuber M, Roden M. Near-Normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open. 2015;5(6):e006559. https://doi.org/10.1136/bmjopen-2014-006559 . Published 2015 Jun 24.
doi: 10.1136/bmjopen-2014-006559
pmcid: 4479996
pubmed: 26109108
Moser JT, Langdon DR, Finkel RS, et al. The evaluation of peripheral neuropathy in youth with type 1 diabetes. Diabetes Res Clin Pract. 2013;100(1):e3–6. https://doi.org/10.1016/j.diabres.2013.01.015 .
doi: 10.1016/j.diabres.2013.01.015
pubmed: 23391743
Gasecka A, Siwik D, Gajewska M, et al. Early biomarkers of neurodegenerative and neurovascular disorders in Diabetes. J Clin Med. 2020;9(9):2807. https://doi.org/10.3390/jcm9092807 . Published 2020 Aug 30.
doi: 10.3390/jcm9092807
pmcid: 7564566
pubmed: 32872672
Lima JE, Takayanagui OM, Garcia LV, Leite JP. Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. Braz J Med Biol Res. 2004;37(1):19–26. https://doi.org/10.1590/s0100-879x2004000100003 .
doi: 10.1590/s0100-879x2004000100003
pubmed: 14689039
Majeed IF, Baban RS, Salman IN, AlRufaie MM. Potential predictive biomarker for diabetic peripheral neuropathy: serum neuron-specific enolase. Curr Issues Pharm Med Sci. 2023;36:227–31. https://doi.org/10.2478/cipms-2023-0039 .
doi: 10.2478/cipms-2023-0039
Ghaib ZJ, Ghudhaib KK, Mohsen FY. Assessment of Neuron Specific Enolase Level and some related biochemical factors in patients with Diabetic Peripheral nerve disorders. Indian J Forensic Med Toxicol. 2021;15:1494–500. https://doi.org/10.37506/ijfmt.v15i3.15515 .
doi: 10.37506/ijfmt.v15i3.15515
Ummer MA, Maiya VS, Hande AG. Effect of photobiomodulation on serum neuron specific enolase (NSE) among patients with diabetic peripheral neuropathy – a pilot study. Diabetes Metab Syndr. 2020;14(5):1061–3. https://doi.org/10.1016/j.dsx.2020.06.065 .
doi: 10.1016/j.dsx.2020.06.065
Elshorbagy HH, Barseem NF, Elsadek AE, et al. Serum neuron-specific enolase and S100 calcium-binding protein B in Pediatric Diabetic Ketoacidosis. J Clin Res Pediatr Endocrinol. 2019;11(4):374–87. https://doi.org/10.4274/jcrpe.galenos.2019.2018.0280 .
doi: 10.4274/jcrpe.galenos.2019.2018.0280
pmcid: 6878350
pubmed: 31067852
Hamed S, Metwalley KA, Farghaly HS, Sherief T. Serum levels of Neuron-Specific Enolase in Children with Diabetic Ketoacidosis. J Child Neurol. 2017;32(5):475–81. https://doi.org/10.1177/0883073816686718 .
doi: 10.1177/0883073816686718
pubmed: 28056586
Moin ASM, Nandakumar M, Diane A, Dehbi M, Butler AE. The role of heat shock proteins in type 1 diabetes. Front Immunol. 2021;11:612584. https://doi.org/10.3389/fimmu.2020.612584 . Published 2021 Jan 14.
doi: 10.3389/fimmu.2020.612584
pmcid: 7873876
pubmed: 33584694
Pourhamidi K, Skärstrand H, Dahlin LB, Rolandsson O. HSP27 concentrations are lower in patients with type 1 diabetes and correlate with large nerve fiber dysfunction. Diabetes Care. 2014;37(3):e49–50. https://doi.org/10.2337/dc13-1780 .
doi: 10.2337/dc13-1780
pubmed: 24558083
Pourhamidi K, Dahlin LB, Boman K, Rolandsson O. Heat shock protein 27 is associated with better nerve function and fewer signs of neuropathy. Diabetologia. 2011;54(12):3143–9. https://doi.org/10.1007/s00125-011-2303-5 .
doi: 10.1007/s00125-011-2303-5
pubmed: 21909836
Hajas G, Kissova V, Tirpakova A. A 10-yr follow-up study for the detection of peripheral neuropathy in young patients with type 1 diabetes. Pediatr Diabetes. 2016;17(8):632–41. https://doi.org/10.1111/pedi.12382 .
doi: 10.1111/pedi.12382
pubmed: 27028140
Lee SS, Han HS, Kim H. A 5-yr follow-up nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus [published correction appears in Pediatr Diabetes. 2011;12(1):74]. Pediatr Diabetes. 2010;11(8):521–528. https://doi.org/10.1111/j.1399-5448.2009.00636.x
Weisman A, Bril V, Ngo M, et al. Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. PLoS ONE. 2013;8(3):e58783. https://doi.org/10.1371/journal.pone.0058783 .
doi: 10.1371/journal.pone.0058783
pmcid: 3606395
pubmed: 23533591